Slides
Page 1
Proteomics International Laboratories Ltd Investor Webinar Disciplined Path to Commercial Success 4 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Page 2
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ) and is dated 4 November 2026. The Company is under no obligation to update or keep the information represented in this presentation current past the date of presenting. All information is subject to change without notice. This presentation contains summary information about the Company as at the date of this presentation (unless otherwise stated) and has been prepared for the purposes of an investor webinar. Risks An investment in the Company is speculative and is subject to a number of known and unknown risks, both specific to the Company’s business and of a general nature, many of which are beyond the control of the Company. These include risks relating to the Company’s future funding requirements, the commercialisation and market adoption of its tests, its reliance on distribution partners, reimbursement, regulatory requirements, clinical performance, intellectual property, key personnel, and general economic and market conditions. Recipients should consider these risks in light of their own investment objectives, financial situation and particular needs (including financial and taxation issues), and should seek advice from their accountant, financial adviser, stockbroker, lawyer, tax adviser or other independent and qualified professional adviser before deciding whether to invest in the Company. Limitation of financial product advice At no time should this presentation be considered to be the giving of financial product advice by the Company, its directors, officers, employees, agents or advisors. The information contained in the presentation has been prepared without regard to the recipients’ financial circumstances or investment objectives, financial situation or particular needs (including financial or taxation issues). It is incumbent upon the recipient to make its own independent assessment of the Company and take independent advice as necessary. Use of third party information Any information or views expressed in this presentation were prepared by the Company. Information contained may have been obtained from publicly available sources that have not been independently verified. No warranty or representation is made to the accuracy of any third-party information contained in this presentation, and no responsibility or liability is accepted by the Company, its directors, officers, employees, agents or advisors for errors, omissions or misstatements made. Past performance Recipients should note that any past performance information given in this presentation is provided for illustrative purposes only and should not be relied upon as, and is not, an indication of the future performance of the Company, including future share price performance. Forward-looking statements This document contains forward-looking statements, including statements concerning the Company’s future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to the Company as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Other factors that may cause such differences include the risks referred to above. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise. 1
Page 3
EXECUTIVE SUMMARY 2 Disciplined Path to Commercial Success Funding the Commercial Plan • SPP launched to raise A$5 million. • SPP opens today, 4 November and closes 25 November 2026 • Funding targeted to commercial execution and expected to support operations to October 2027 Commercial Milestones • Reorganised the business and reduced operating costs • Secured Healius as exclusive Australian pathology distributor • Commenced national rollout of Promarker D and Eso • Completed independent validation of Promarker Endo Growth Drivers • Increase awareness and adoption of Promarker tests in Australia • Target Promarker Endo launch in January–March 2027 • Target an initial US distributor appointment in H2 FY27 • Advance reimbursement in Australia and the US • Improve laboratory efficiency and capacity Proteomics International has secured Healius as exclusive distributor and begun the national rollout of Promarker D and Eso. Next, we are targeting the Endo launch in early 2027, the appointment of a US distributor and advancing reimbursement. The proposed A$5 million raise is expected to fund these milestones and support operations to October 2027.
Page 4
COMPANY OVERVIEW About Us Proteomics International (ASX: PIQ) develops proprietary blood tests for disease prediction and diagnosis. We deliver laboratory testing and clinical reporting, while distribution partners provide market access to clinicians and patients. Target Unmet Clinical Needs • Identify high value diagnostic gaps • Target diseases with delayed or inadequate diagnosis • Focus on tests that can improve clinical decision making Build the Promarker® Portfolio • Promarker®D: diabetic kidney disease • Promarker®Eso: oesophageal cancer • Promarker®Endo: endometriosis • Advance new tests through the development pipeline Operate Integrated Clinical Laboratories • Accredited NATA laboratory operations in Australia • CLIA/CAP laboratory capability in the US • Deliver testing, clinical reporting and quality assurance • Scale operations to support commercial demand Drive Market Access • Distributor-led commercial model • Healius partnership provides national Australian access • Private-pay launch while reimbursement is pursued • Build US distribution and payer access Leverage our Proprietary Platform • Discover disease- associated protein biomarkers • Combine biomarkers into proprietary test models • Develop and clinically validate new diagnostic tests • Protect innovation through intellectual property 3
Page 5
Innovation Portfolio – Four Tests Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical conditions. Promarker D Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Promarker Eso Diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures. Promarker Endo Diagnostic blood test for patients with symptoms suggestive of endometriosis, that reduces the extensive delays in diagnosis and management. OxiDx Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits. 4 PORTFOLIO
Page 6
Promarker D Innovation Portfolio – Three Promarker Tests Clinical Value Clinical Performance Clinical Pathway Value Proposition The Promarker Portfolio tests address distinct clinical pathways, supporting earlier risk identification, more targeted referral and more efficient use of healthcare resources. Identifies Type 2 Diabetes (T2D) patients at higher risk of diabetic kidney disease 76% Sensitivity, 92% Specificity Diabetes management and renal-risk pathways Earlier intervention and lower downstream kidney disease costs Promarker Eso Promarker Endo Triages reflux patients for endoscopy referral 91% Sensitivity, 98% Specificity GI referral pathways with potential to reduce unnecessary endoscopy Avoiding unnecessary invasive procedures Supports assessment of women with suspected endometriosis Sensitivity is 90% for stage IV, 84% for stages III–IV, 80% for stages II–IV, and 68% for stages (I–IV). Specificity is 71% across all groups. Women’s health pathways and earlier specialist referral Faster diagnosis and more effective management Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model’s ability to distinguish between classes (disease versus no disease). 5 PORTFOLIO
Page 7
Innovation Portfolio – Market Potential Market opportunities for the three main tests were evaluated across Australia and the United States. The analysis indicated a sizeable serviceable obtainable market with significant growth potential. Australian patient pricing is set for Promarker D and Promarker Eso, equating to indicative revenue of A$25 million per annum at serviceable obtainable volumes. Sources: Population data from ABS and U.S. Census Bureau 2025 estimates. Promarker D: AIHW/NDSS (AU); U.S. Census Bureau/CDC (US). Promarker Eso: AIHW/RACGP (AU); NIDDK/U.S. reflux studies (US). Promarker Endo: ABS/AIHW (AU); U.S. Census Bureau/women’s health literature (US). Market Potential Australia – Annual Test Volumes (‘000) Market Potential USA – Annual Test Volumes (‘000) 50 15 20 100 60 115 130 90 195 0 50 100 150 200 Promarker Endo Promarker Eso Promarker D TAM SAM SOM 360 240 390 1,200 960 2,600 1,500 1,400 4,400 0 1,000 2,000 3,000 4,000 Promarker Endo Promarker Eso Promarker D TAM S AM SOM Definitions: Total Addressable Market (TAM) assumes unconstrained access and reimbursement. Serviceable Available Market (SAM) considers challenges associated with pathway, workflow, and reimbursement. Serviceable Obtainable Market (SOM) reflects realistic medium-term commercial penetration opportunities. 1. Promarker D assumptions: T2D patients in active care, pre-advanced CKD. Tested once every 4 years. 65% of diagnosed T2D addressable. SAM 60% of TAM; SOM 15% of SAM. 2. Promarker Eso assumptions: Chronic reflux patients with appropriate risk factors. Tested once every 3 years. 15% of managed reflux patients. SAM 70% of TAM; SOM 25% of SAM. 3. Promarker Endo assumptions: Reproductive-age women (15–49) with suspected endometriosis. Tested once per clinical work-up. 10% prevalence; 55% undiagnosed; 35% enter active work-up annually. SAM 80% of TAM; SOM 30% of SAM. 6 MARKET POTENTIAL
Page 8
Healius Distribution Partnership Exclusive Australian pathology distribution for the Promarker® portfolio. Healius provides national market access through its collection network and referrer relationships, while Proteomics delivers testing and clinical reporting. DISTRIBUTION MODEL Commercial Rollout • Commenced Promarker D and Promarker Eso Australian national rollout on 26 October 2026 • Initial private pay patient prices: Promarker D A$495 and Promarker Eso A$997. • Promarker Endo commercially available during FY27 Q3, pricing to be confirmed. Proteomics • Performs testing in accredited laboratories. • Provides clinical reporting and scientific support. • Maintains quality and regulatory compliance. • Leads product development and clinical evidence. • Exclusive Australian pathology distributor. • Approximately 1,900 collection centres. • Collects specimens and distributes pathology services. • Supports referrer engagement and market access. Strategic Rationale • National reach through existing pathology infrastructure. • Access established GP and specialist referrers. • Avoid building a proprietary collection network. • Integrate tests into routine clinical workflows. 7
Page 9
Execution Plan – The Next 3 Years The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. STRATEGIC ROADMAP RESET FY26 H2 Discontinued the DTC business model Engaged with potential distribution partners in Australia and the USA Continued Promarker Endo assay validation Refinement of Promarker Eso assay and streamlined lab protocols Restructured the leadership team and organisation Commenced the OxiDX strategic review Reviewed IP portfolio ADVANCE FY27 H2 • Promarker Endo commercially available in Australia • Appoint distributor partner in the USA • Establish Proteomics team in the USA • Optimise test turnaround times, reporting, and customer experience • Prepare reimbursement dossiers and commence submissions for Australia and USA ACCELERATE FY28 • Broaden distributor network coverage • Increase awareness and test utilisation across clinical indications • Expand laboratory capacity and support functions in line with demand • Manage reimbursement submissions and engagement processes • Publish clinical utility and health economic evidence to support adoption and reimbursement ACHIEVE FY29 • Enhance distributor performance management • Expand product portfolio pipeline • Streamline laboratory and commercial operations • Improve operating leverage • Develop strategic growth options to drive product and geographic expansion ACCESS FY27 H1 Advanced laboratory processes, quality systems, and information systems in Australia Appointed distributor partner in Australia Commence commercial release of Promarker D and Promarker Eso in Australia Develop reimbursement strategy for Australia and the USA Refined and Validated Promarker Endo 8
Page 10
CAPITAL RAISE Share Purchase Plan An opportunity for eligible shareholders to participate in Proteomics’ growth. OFFER PRICE PER NEW SHARE A$0.10 12.2% discount to 5-day VWAP Maximum application A$30,000 Target SPP proceeds A$5m Free attaching option Subject to Shareholder approval 1:1 COMMERCIAL PROGRESS Healius partnership National distribution partnership secured Australian rollout Promarker D and Promarker Eso rollout underway • Commercial execution • US market entry • Clinical evidence • Reimbursement • Laboratory efficiency and capacity ELIGIBLE SHAREHOLDERS Australia & New Zealand, Record date: 30 October 2026 OFFER OPENS 4 November 2026 OFFER CLOSES 25 November 2026 12 Next milestone Promarker Endo launch targeted for January–March 2027 FUNDING THE NEXT STAGE OF GROWTH *Indicative only and may be extended.
Page 11
Sources and Uses of Funds CAPITAL RAISE 10 A$9.1m SOURCES OF FUNDS Cash at 30 September 2026 1.8 R&D tax refund received 2.0 Other income (forecast) 0.3 Assumed gross SPP proceeds 5.0 USES OF FUNDS A$ million SPP offer booklet with full details and timetable lodged with ASX on 4 November 2026 Research and product development 2.0 Clinical evidence and reimbursement 1.6 Commercial execution and market access 1.6 Laboratory operations and capacity 1.4 Corporate costs and working capital 2.5
Page 12
Proteomics International Laboratories Ltd APPENDIX 4 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Page 13
Dr James Williams Non- Executive Chair PhD, MBA, BSc (Hons) GAICD Seasoned life sciences executive with experience from startup to commercialisation. Former CEO/CTO/Chair across multiple biotech companies including Dimerix and iCeutica. Contributed to development of five FDA-approved drugs, devices, and diagnostics. Vicki Robinson Non-Executive Director LLB (Hons), BCom, MAICD Experienced non-executive and former Wesfarmers senior executive with 20+ years in legal and commercial leadership. Served on Wesfarmers Leadership Team and as Company Secretary across group entities. Deep experience in strategy, M&A, governance, risk, and regulatory environments. Paul House Non-Executive Director BEng (Hons), GAICD Senior executive with 25+ years across multinational corporations and consulting. CEO of Imdex (ASX: IMD); former MD of SGS India and CFO/COO in global roles. Strong track record in operational leadership, finance, and international growth. Aaron Brinkworth Non-Executive Director BHIthSc, GAICD Global pharmaceutical executive with 22+ years at Gilead Sciences (Nasdaq: GILD). Led Asia Pacific commercial, market access, and strategic licensing functions. Deep experience in scaling sales, marketing, and distribution across complex regions. David Morris CEO & Managing Director BBus, BAppSc, GAICD Global healthcare and medtech executive with 25+ years experience including at Cochlear, Nanosonics and Polynovo. Proven track record in commercial growth, product commercialisation, and international expansion. Deep experience in strategy, regulatory pathways, and global market development across US, Europe, and Asia. Board of Directors 12 LEADERSHIP
Page 14
Science of Proteomics Genes carry the instructions. Proteins reveal how those instructions play out in health and disease. Translating that insight into reliable diagnostic and prognostic tests requires precision, standardisation and deep technical expertise. Genes Provide the Instructions Genes are sections of DNA that contain instructions for making proteins. Cells use these instructions to produce the proteins the body needs. Proteins Perform Biological Functions Proteins build and repair tissues, regulate cell activity and drive biological reactions. Proteomics studies proteins to understand what is happening in the body. Protein Changes Signal Disease Disease can alter the levels of particular proteins. Measuring combinations of these changes can help identify disease or assess the risk of developing it. Measure Proteins to Detect Disease Proteomics International identifies protein biomarkers and develops simple blood tests that measure them, to help clinicians assess disease risk and support diagnosis. Protein A increases Protein B decreases Typical level Example with disease 13 PLATFORM
Page 15
Strategic Framework for Execution Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners, and investors. ENTERPRISE PRIORITIES DRIVE COMMERCIAL EXECUTION • Transform clinically validated diagnostics into a scalable business model • Establish distributor led market access in Australia and the USA • Promote adoption via phased market launches • Integrate tests into routine clinical practice • Secure reimbursement and payer coverage with robust evidence OPTIMISE OPERATIONS • Deliver dependable test access with scalable, consistent service • Implement standardised systems and workflows • Expand laboratory operations in response to demand • Increase efficiency in turnaround times and throughput • Strengthen quality control and regulatory compliance BUILD ORGANISATION CAPABILITIES • Establish a clear structure, roles and responsibilities • Strengthen leadership capabilities • Attract and retain key technical and commercial talent • Embed disciplined performance management • Foster a culture centered on commercialisation, execution, quality, and compliance DELIVER SUSTAINABLE VALUE • Prioritise growing revenue and sustainable profit margins • Maintain capital efficiency alongside rigorous cost control • Adopt a proactive approach to risk management • Develop strategic growth options through partnerships to drive expansion • Increase long term shareholder value INNOVATE PORTFOLIO • Develop products with strong commercial and reimbursement potential • Conduct biomarker research based on clear clinical needs • Maintain strict scientific and clinical standards • Produce dependable clinical and economic evidence • Ensure robust intellectual property portfolio 14
Page 16
Patient Care Ecosystem Patient Clinician Pathology Network Proteomics The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to result. IDENTIFY ANALYSE INFORM ACT COLLECT Presents and consents Provide blood sample Receives results via clinician Receives personalised care advice Assesses and orders test Interprets test result Manages treatment or referral Enables access and ordering Collects blood and manages logistics Tracks samples and turnaround Supports report delivery Supports repeat testing Defines indications Sets collection standards Performs testing and quality control Issues decision ready report Captures outcomes 15 CLINICAL PATHWAY
Page 17
PRODUCT OVERVIEW 16 Promarker D – Chronic Kidney Disease Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Clinical Value Identifies high risk patients with diabetes before irreversible kidney damage occurs. Market Opportunity SOM reflects realistic medium term annual commercial opportunities. ~20,000 patients in Australia and ~390,000 in the USA. Clinical Performance 76% sensitivity, 92% specificity, NPV 95%, AUC 0.78 Multi year validation completed. Clinical Pathway Blood sample taken during regular diabetes check ups guides monitoring by GPs and nephrologists and is done every 4 years. Intellectual Property Global patent portfolio covering biomarkers, and clinical applications. Key Actions • Collaborate with Healius on Australian national rollout • Appoint distributor partner in the USA • Leverage clinical advisory board to increase awareness • Complete Australian health economics study to support reimbursement • Commence reimbursement applications in Australia • Prepare dossier for US reimbursement • Increase lab capacity to meet demand and improve turnaround times Reimbursement Initial private pay in Australia and the USA, with plans for insurance and public funding; obtained the CMS PLA code in USA. Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model’s ability to distinguish between classes (disease versus no disease). Note 2: CMS (Centers for Medicare & Medicaid Services). PLA (Proprietary Laboratory Analysis) A code recognised by CMS that uniquely identifies a specific proprietary clinical laboratory test for Medicare pricing and billing purposes.
Page 18
SYMPTOMS PATIENT JOURNEY Promarker D – Chronic Kidney Disease Promarker D enables a shift from reactive CKD treatment to proactive risk-based care, identifying risk earlier, guiding targeted intervention, and helping reduce late-stage cost burden. EVALUATION MANAGEMENT Promarker D Standard of Care Sources: National Kidney Foundation; CDC; KDIGO 2024 CKD Guideline; Peters et al. (2019); NICE MIB312 (2022); Fusfeld et al. (2022); AIHW Chronic Kidney Disease: Australian Facts; Essue et al., BMC Nephrology (2013); Randall et al., BMC Health Services Research (2024). Risk Becomes Visible • Routine diabetes testing flags CKD risk • Earlier insight supports monitoring and prevention Earlier Prognostic Insight • Blood-based triage added to routine diabetes care • Flags risk up to four years before damage Care Starts Sooner • High-risk patients prioritised for therapy and monitoring • Low-risk patients may avoid unnecessary escalation CKD Remains Hidden • CKD can progress silently in type 2 diabetes • Symptoms may appear after significant kidney damage Diagnosis Follows Damage • eGFR and uACR confirm damage after it occurs • Irreversible damage may already be present Care Intensifies Late • Treatment escalates after CKD is confirmed • Late-stage care may require dialysis or transplant Value Proposition 17 Time Horizon Up to 4 years earlier risk insight Vs 5–15 years silent CKD Patient Journey Routine GP test triage Vs ~1 in 2 T2D patients develop CKD Economic Burden (SoC) Initial private pay A$495 Vs Monitoring CKD ~A$3K pa, Dialysis ~A$50K to A$85K pa
Page 19
PRODUCT OVERVIEW 18 Promarker Eso – Oesophageal Cancer Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures. Clinical Value Identifies patients with chronic reflux at risk of oesophageal cancer, reducing the need for invasive surveillance endoscopic procedures. Market Opportunity SOM reflects realistic medium term annual commercial opportunities. ~15,000 patients in Australia and ~240,000 in the USA. Clinical Performance 91% sensitivity, 98% specificity, NPV 99.9%, AUC exceeding 0.98. Assay being validated across multiple cohorts. Clinical Pathway Blood sample taken during regular check ups guides monitoring by GPs and gastroenterologists and is done every 3 years. Intellectual Property Globally granted patent family protecting key biomarkers and clinical applications. Reimbursement Initial private pay in Australia and the USA, with plans for insurance and public funding. Key Actions • Collaborate with Healius on Australian national rollout • Appoint distributor partner in the USA • Leverage clinical advisory board to increase awareness • Complete Australian health economics study to support reimbursement • Commence reimbursement applications in Australia • Prepare dossier for US reimbursement • Increase lab capacity to meet demand and improve turnaround times Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model’s ability to distinguish between classes (disease versus no disease).
Page 20
SYMPTOMS PATIENT JOURNEY Promarker Eso – Oesophageal Cancer Promarker Eso could shift oesophageal cancer risk assessment from procedure-led surveillance to a faster, lower-burden blood-test triage pathway. EVALUATION MANAGEMENT Promarker Eso Standard of Care Sources: Sheahan et al., Proteomes (2025); Wani et al., Gastroenterology (2025); Pilonis et al., Lancet Oncology (2022); Holmberg et al., eClinicalMedicine (2023); Medical Costs Finder & CostDoc, Endoscopy Cost (2026). Routine Symptom Management • Chronic reflux managed with medication • Referral after repeat GP/PPI therapy Endoscopy-Led Evaluation • Specialist referral adds time, cost and anxiety • Endoscopy requires sedation and time off work Broad Surveillance Pathway • Similar surveillance for low- and high-risk patients • Late detection remains a recognised shortcoming Value Proposition 19 Time Horizon Blood-test triage in weeks Vs 1–3+ years repeat management Patient Journey Lower-burden blood test triage Vs Endoscopy pathway Economic Burden (SoC) Initial private pay A$997 Vs Endoscopy cost A$500 to A$2,500 every 2 to 3 years Measurable Risk Insight • Blood test indicated for appropriate chronic reflux patients • Risk information added to routine clinical management Earlier Risk Stratification • Blood-based triage supports referral decisions • No sedation, scheduling or time off work Targeted Care Decisions • Low-risk patients continue GP led reflux care • High-risk patients prioritised for endoscopy review
Page 21
PRODUCT OVERVIEW 20 Promarker Endo – Endometriosis Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management. Promarker Endo test has now been refined and independently validated. Clinical Value Identifies patients with a high risk of endometriosis, shortening the typical 8 year delay in diagnosis. Market Opportunity SOM reflects realistic medium term annual commercial opportunities. ~50,000 patients in Australia and ~360,000 in the USA. Clinical Performance Sensitivity is 90% for stage IV , 84% for stages III–IV , 80% for stages II–IV , and 68% for stages (I–IV). Specificity is 71% across all groups. Clinical Pathway Blood sample is taken to help GPs and gynaecologists evaluate patients who may have endometriosis. Intellectual Property Broad international patent portfolio with initial patents secured. Reimbursement Initial private pay in Australia and the USA, with plans for insurance and public funding. Key Actions • Finalise assay refinement, clinician reporting guidance and regulatory requirements • Launch in Australia through Healius, expected Q3 FY27, and confirm pricing • Appoint distributor partner in the USA • Establish clinical advisory boards to increase awareness • Complete Australian health economics study to support reimbursement • Prepare dossier for US reimbursement • Increase lab capacity to meet demand and improve turnaround times Note 1: Sensitivity (True Positive Rate), The proportion of actual positives correctly identified. Specificity (True Negative Rate) The proportion of actual negatives correctly identified. NPV (Negative Predictive Value) The probability that someone with a negative test truly does not have the condition. AUC (Area Under the ROC Curve) A summary measure of a model’s ability to distinguish between classes (disease versus no disease).
Page 22
SYMPTOMS PATIENT JOURNEY Promarker Endo – Endometriosis Promarker Endo could shorten the path from symptoms to clarity, using a blood-test risk triage to support earlier referral and more targeted care. Promarker Endo test has now been refined and independently validated. EVALUATION MANAGEMENT Promarker Endo Standard of Care Sources: AIHW Endometriosis in Australia (2023); Nnoaham et al., American Journal of Obstetrics & Gynecology (2019); Crump et al., AJGP (2024); ESHRE Guideline (2022); RANZCOG Endometriosis Guideline (2024); Armour et al., PLOS One (2019); Schoeman et al., Human Reproduction (2025) Symptoms Often Normalised • Pelvic pain and fatigue may be normalised • Multiple consultations Diagnosis Takes Years • GP, imaging and specialist review before confirmation • 4–11 yrs to diagnosis; including imaging, and laparoscopy Care Escalates Late • No definitive care pathway • Delayed care adds pain, fertility risk and quality of life burden Value Proposition 21 Time Horizon Weeks to diagnosis Vs typical 8 year delay in diagnosis Patient Journey Blood-test triage Vs Imaging and laparoscopy pathway Economic Burden (SoC) Average cost per patient is A$3K to $5K pa, plus significant cost of lost productivity Symptoms Assessed Objectively • Objective blood-test risk insight • Fewer repeat consultations Earlier Risk Stratification • Blood-based triage guides referrals • Clarity in weeks, not years Risk-Guided Intervention • Earlier referral for at-risk patients • Treatment focused on likely benefit
Page 23
Proteomics International Laboratories Ltd ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia